NRA-0160 is a selective dopamine D4 receptor antagonist used in neuroscience research to study dopaminergic systems; it reverses the effects of methamphetamine (MAP) and apomorphine (APO) on A9 and A10 dopamine neurons, with greater potency on A10 neurons; it does not affect PCP-induced hyperlocomotion, stereotypy, ataxia, or extracellular glutamate levels in rats.